MECFA Blog

News & Articles

Startup Arrevus developing drug that could extend lifespan of cystic fibrosis patients

Cystic fibrosis (CF) is a heredity disease with no cure. However, biotech startup Arrevus is working on a drug that could potentially extend the lifespans of those living with the disease. The Raleigh-based firm recently received a $250,000 loan from the North Carolina Biotechnology Center to support the development of its Phase 3 drug candidate ARV-1801 for the treatment of pulmonary exacerbations in CF patients. These episodes of “acute worsening of pulmonary status” occur frequently in patients with cystic fibrosis, and result in a sequential and permanent decline in lung function. “All CF patients encounter these exacerbations — twice or maybe three times a year — where they’re coughing,

Rare Cystic Fibrosis Mutations Dominate in Caribbean Patients

NEW YORK – Cystic fibrosis patients from Puerto Rico and the Dominican Republic carry different genetic variants in the CFTR gene than most CF patients, a new sequencing-based study has found, which could impair their ability to benefit from screening or treatment with new targeted therapies. While most of the 80,000 people across the globe who have cystic fibrosis are white, the percentage of CF patients who are Latino has climbed from 5.6 percent to 8.7 percent in the last 15 years, and the course of the disease is more severe for them. Alterations to the CFTR gene, which encodes a chloride channel, cause cystic fibrosis, and about 2,000 such mutations have been identified. Researchers led

Disease-causing protein in cystic fibrosis has ancient roots in sea lamprey

The oldest known ortholog of the ion channel that is defective in patients with cystic fibrosis arose approximately 450 million years ago in the sea lamprey, researchers report October 31st in the journal Developmental Cell. Many differences between lamprey and jawed vertebrate orthologs of this protein, called the cystic fibrosis transmembrane conductance regulator (CFTR), are vestiges of the evolutionary transition from a transporter to a specialized chloride and bicarbonate channel. Other differences likely reflect later adaptation of the sea lamprey to its specific environment. "This study shows, for the first time, that CFTR existed with the basic function as an ion channel earlier than

This 3-drug combo can improve lungs affected by cystic fibrosis

A phase three clinical trial conducted by UT Southwestern led to the conclusion that a three-drug blend could enhance lung functions and bring down the symptoms of cystic fibrosis (CF) for patients. Most of them possess a single copy of the most prevalent genetic mutation for the illness. The therapy was approved in the beginning of the month by the Food and Drug Administration. It was based on an international research published today in the New England Journal of Medicine. There was also another probe that was published in The Lancet. It gave a report on those who had one or two copies of the mutation. Dr. Raksha Jain, Associate Professor of Internal Medicine at UT Southwestern Medical Cen

Long-awaited cystic fibrosis drug could turn deadly disease into a manageable condition

A new cystic fibrosis therapy dramatically improved patients’ lung function and showed clear signs of targeting the genetic root of the disorder, instead of just alleviating symptoms—a breakthrough so long-sought that many doctors and patients are moved to tears when talking about it. The data, unveiled Thursday at a national conference in Tennessee and simultaneously published in two leading medical journals, was so persuasive that the Food and Drug Administration recently approved the three drug combination, called Trikafta—five months ahead of the agency’s deadline. The drug could benefit 90 percent of patients with the disease, a major advance over previous drugs that worked in a tiny fr

The surprising drugs that could help curb depression, according to new study -Some aren't convin

A new study has found that painkillers, statins and fish oils may help curb depression, especially if taken with antidepressants. The review found that anti-inflammatory agents, including painkillers such as ibuprofen and aspirin, as well as statins and omega-3 fish oils, could curb major symptoms of depression such as low mood. Experts from the University of Science and Technology in Wuhan, China, reviewed 26 existing studies for their research in the Journal of Neurology, Neurosurgery and Psychiatry. The anti-inflammatories included in the studies were non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin; omega 3 fatty acids often found in fish oils; cytokine inhibi

Featured Posts
Recent Posts
Archive
Search By Tags

Support Zahra's run for Palestine CF patients.

  • Facebook Clean
  • Twitter Clean
  • Instagram - Grey Circle
  • YouTube - Grey Circle
  • LinkedIn Clean